GlassScriptPhysician profile
Andrew S Raxenberg
NPI 1841388758
$2,429.71
in general payments reported to CMS, 2019-2025
25 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $187 · 2021: $278 · 2022: $284 · 2023: $508 · 2024: $462 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $564.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $207.45 | 2019-2025 | Repatha, Evenity, Otezla |
| Abbott Laboratories | $192.08 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $165.84 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $165.16 | 2023 | Cobalt Dr Mri Surescan |
| Kowa Pharmaceuticals America, INC. | $132.44 | 2019-2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $128.05 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $119.60 | 2021-2024 | Shingrix, Arexvy |
| Abbvie INC. | $115.37 | 2021-2024 | |
| Amarin Pharma, INC. | $86.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $72.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $70.77 | 2019-2023 | |
| Lilly USA, LLC | $67.40 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $66.96 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $60.86 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.75 | 2019 | |
| Sunovion Pharmaceuticals INC. | $31.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.87 | 2025 | |
| Eisai INC. | $21.51 | 2025 | |
| Astellas Pharma US INC | $19.66 | 2021 | |
| Philips North America LLC | $19.14 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Sumitomo Pharma America, INC. | $18.93 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.19 | 2024 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $14.80 | 2025 | Onpattro |
| Merck Sharp & Dohme LLC | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Raxenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.